dc.contributor.advisor | Paulssen, Ruth | |
dc.contributor.author | Meng, Wei | |
dc.date.accessioned | 2024-12-19T14:20:43Z | |
dc.date.available | 2024-12-19T14:20:43Z | |
dc.date.issued | 2025-01-10 | |
dc.description.abstract | Ulcerative Colitis (UC) is a chronic autoimmune inflammatory disease and one type of inflammatory bowel disease (IBD). UC is characterized by a temporal course of remission and relapse. Environmental factors, immune system dysregulation, and genetic susceptibility interact intricately in the aetiology of UC. It is unclear how interactions involving non-coding RNAs (ncRNAs), epigenetic modifications, and genetic changes relate to active UC, remission, and relapse. The inability to predict relapse in patients with UC poses a challenge to current treatment options. Visible disease manifestations, which are usually absent in patients in remission, frequently place limitations on the use of clinical diagnostic methods. Thus, it is necessary to characterize remission at the molecular level. To investigate the molecular mechanisms in remission and active UC, data from whole transcriptome sequencing (RNA-seq) and whole genome bisulfite sequencing (WGBS) of mucosal biopsies have been analysed with a variety of bioinformatic methods The analyses resulted in the identification of a set of mitochondrial RNAs and small nuclear RNAs (snoRNAs) which may influence the duration of remission. Several identified remission-specific genes are involved in pro- and anti-inflammatory pathways and some of the identified genes may be regulated by DNA methylation. In addition, several DNA-methylated long non-coding RNAs (lncRNAs) have been found to be involved in UC inflammatory immune responses. These findings might shed light on the pathophysiology of UC and suggest new diagnostic markers. | en_US |
dc.description.doctoraltype | ph.d. | en_US |
dc.description.popularabstract | Ulcerative colitis (UC) is a chronic inflammatory disease. The increasing incidence of UC worldwide is of global concern and is a burden to the healthcare system. The exact cause of UC is unknown. Several factors including environment, genetics, and immune responses contribute to UC onset. As a chronic disease, UC cannot be cured and has both active and inactive states. The treatment goal is to maintain UC patients in an inactive state (remission). Patients in remission relapse frequently and there are no existing methods for reliable prognosis of relapse. Although studies have intensively focused on active UC, the state of remission is not well understood. The application of sequencing data together with bioinformatic analysis may provide a better understanding of UC in remission at a molecular level and might identify potential predictors for relapse. The results might improve patient outcomes and UC management. | en_US |
dc.identifier.uri | https://hdl.handle.net/10037/36055 | |
dc.language.iso | eng | en_US |
dc.publisher | UiT The Arctic University of Norway | en_US |
dc.publisher | UiT Norges arktiske universitet | en_US |
dc.relation.haspart | <p>Paper I: Meng, W., Johnsen, K.M., Fenton, C.G., Florholmen, J. & Paulssen, R.H. (2023). Anti-apoptotic genes and non-coding RNAs are potential outcome predictors for ulcerative colitis. <i>Functional Integrative Genomics, 23</i>, 165. Also available in Munin at <a href=https://hdl.handle.net/10037/30661>https://hdl.handle.net/10037/30661</a>.
<p>Paper II: Meng, W., Fenton, C.G., Johnsen, K.M., Taman, H., Florholmen, J. & Paulssen, R.H. (2024). DNA methylation fine-tunes pro-and anti-inflammatory signalling pathways in inactive ulcerative colitis. <i>Scientific reports, 14</i>, 6789. Also available in Munin at <a href=https://hdl.handle.net/10037/34824>https://hdl.handle.net/10037/34824</a>.
<p>Paper III: Fenton, C.G., Ray, M.K., Meng, W. & Paulssen, R.H. (2023). Methylation-Regulated Long Non-Coding RNA Expression in Ulcerative Colitis. <i>International Journal of Molecular Sciences, 24</i>(13), 10500. Also available in Munin at <a href=https://hdl.handle.net/10037/29934>https://hdl.handle.net/10037/29934</a>. | en_US |
dc.relation.isbasedon | Data available at the National Center for Biotechnology Information under numbers <a href=https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128682>GSE128682</a> and <a href=https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169360>GSE169360</a>. The data used in validation includes GSE109142, GSE128682, GSE206285, GSE36807, GSE38713, GSE47908, GSE13367, GSE16879, GSE48958, GSE59071, and GSE73661. | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2025 The Author(s) | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.subject | Ulcerative Colitis | en_US |
dc.subject | Remission | en_US |
dc.subject | Sequencing | en_US |
dc.subject | DNA methylation | en_US |
dc.subject | LncRNA | en_US |
dc.title | Novel Molecular Characteristics of Ulcerative Colitis | en_US |
dc.type | Doctoral thesis | en_US |
dc.type | Doktorgradsavhandling | en_US |